Cargando…

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

BACKGROUND: Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myeloma-targeted antibodies, and histone deacetylase inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Joel G., Dawson, Jana L., Grant, Steven, Shain, Kenneth H., Dalton, William S., Dai, Yun, Meads, Mark, Baz, Rachid, Kauffman, Michael, Shacham, Sharon, Sullivan, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997728/ https://www.ncbi.nlm.nih.gov/pubmed/27557643 http://dx.doi.org/10.1186/s13045-016-0304-z

Ejemplares similares

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo
por: Turner, Joel G., et al.
Publicado: (2013)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

A pharmacodynamic model of clinical synergy in multiple myeloma
por: Sudalagunta, Praneeth, et al.
Publicado: (2020)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

Heterozygous mutation of cysteine(528) in XPO1 is sufficient for resistance to selective inhibitors of nuclear export
por: Neggers, Jasper Edgar, et al.
Publicado: (2016)

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
por: Yoshimura, Mariko, et al.
Publicado: (2014)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
por: Sellin, Mark, et al.
Publicado: (2022)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
por: Binder, Adam F., et al.
Publicado: (2023)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma
por: Kareem, Syeda Saba, et al.
Publicado: (2022)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

State-of-the-Art Management of Complications of Myeloma and Its Treatment
por: Hartley-Brown, Monique A., et al.
Publicado: (2010)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

P-115: Unc-51 Like Kinase 3 protein (ULK3)-mediated autophagy is responsible for multiple myeloma resistance to chemotherapy
por: Tauro, Marilena, et al.
Publicado: (2022)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Effects of DNA topoisomerase IIα splice variants on acquired drug resistance
por: Elton, Terry S., et al.
Publicado: (2020)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review
por: Nishihori, Taiga, et al.
Publicado: (2017)

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
por: Lage, H, et al.
Publicado: (2000)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication
por: Mathew, Cynthia, et al.
Publicado: (2021)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
por: Wang, Di, et al.
Publicado: (2023)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

XPO1-dependent nuclear export as a target for cancer therapy
por: Azizian, Nancy G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h2i4icaai94a0oq2tvrmirtde0